Nebraska Medical Cannabis Program: Laws, Eligibility & Dispensaries

Executive Summary

Nebraska's Supreme Court upheld the validity of the state's medical cannabis laws on September 4, 2026, clearing the final legal obstacle for implementation of a voter-approved program that had faced years of constitutional challenges. The ruling marks a watershed moment for Nebraska, which became one of the last states in the region to authorize medical marijuana after voters approved Initiative 437 and Initiative 438 in November 2024. The decision allows the Nebraska Department of Health and Human Services to proceed with licensing dispensaries, cultivation facilities, and testing laboratories across the state. Patients with qualifying conditions including cancer, glaucoma, post-traumatic stress disorder, and chronic pain will gain legal access to medical cannabis products for the first time in state history. The court's decision rejected arguments that the ballot measures violated Nebraska's single-subject rule and that the program conflicted with federal law. Implementation is expected to begin in early 2027, with the first dispensaries projected to open by mid-year. The program will operate under strict regulatory oversight, with possession limits capped at 2.5 ounces per 14-day period and home cultivation prohibited.

Why This Matters

The Nebraska Supreme Court ruling affects approximately 1.97 million state residents and positions Nebraska as the 38th state to authorize medical cannabis, ending its status as one of only 12 states without any form of legal marijuana program. The decision carries immediate implications for multiple stakeholder groups. An estimated 50,000 to 75,000 Nebraska patients are projected to qualify for the medical cannabis program based on demographic analysis and qualifying condition prevalence rates from comparable states, according to the Nebraska Department of Health and Human Services. These patients previously faced criminal penalties for possession or were forced to travel to neighboring states with medical programs, including Iowa, Missouri, and South Dakota. The ruling unlocks a projected $50 million to $80 million annual medical cannabis market in Nebraska by year three of operations, based on per-capita spending patterns in similar rural states. Multi-state operators including Trulieve, Curaleaf, and Green Thumb Industries have expressed interest in entering the Nebraska market, while local entrepreneurs have already submitted preliminary applications for cultivation and dispensary licenses. Healthcare providers across Nebraska's 93 counties will need to navigate new responsibilities as certifying physicians. The Nebraska Medical Association, which remained neutral during the ballot initiative campaigns, has begun developing continuing education programs for physicians who choose to recommend medical cannabis to patients. Law enforcement agencies face operational changes as possession of up to 2.5 ounces transitions from a criminal offense to a legal activity for registered patients. The Nebraska State Patrol and county sheriffs have requested additional training resources and clarification on roadside testing protocols. Tax revenue projections estimate $8 million to $12 million annually from the program's 7% excise tax on medical cannabis sales, with funds designated for regulatory oversight, substance abuse treatment programs, and public education campaigns. Rural counties that approve dispensary locations will receive additional property tax revenue and economic development benefits.

Background and History

Nebraska's path to medical cannabis legalization spans more than a decade of failed legislative efforts, grassroots organizing, and legal battles that culminated in the 2024 ballot initiative victory and subsequent court challenges.

Early Legislative Attempts (2014-2020)

The first serious legislative proposal for medical cannabis in Nebraska emerged in 2014 when State Senator Tommy Garrett introduced LB 643, which would have created a limited medical cannabis program for patients with debilitating conditions. The bill died in committee without advancing to floor debate, reflecting the conservative political climate in the unicameral legislature. Between 2015 and 2019, lawmakers introduced six additional medical cannabis bills, each failing to gain sufficient support for advancement. State Senator Anna Wishart became the primary legislative champion, introducing LB 110 in 2019, which proposed a comprehensive medical program with dispensaries and cultivation facilities. The bill received a public hearing but stalled in the Judiciary Committee amid opposition from law enforcement groups and Governor Pete Ricketts, who consistently opposed any form of cannabis legalization.

First Ballot Initiative Attempt (2020)

Frustrated by legislative gridlock, advocacy group Nebraskans for Medical Marijuana launched a ballot initiative campaign in 2019 to place medical cannabis legalization before voters in November 2020. The campaign, led by State Senator Anna Wishart and cannabis reform advocate Crista Eggers, collected more than 190,000 signatures—well above the 121,000 required threshold. However, Nebraska Secretary of State Bob Evnen rejected the petition in August 2020, citing technical deficiencies in the signature-gathering process. The campaign filed suit in Lancaster County District Court, but the legal challenge failed to restore ballot access before the November election. The setback demonstrated the procedural obstacles facing citizen-led initiatives in Nebraska's restrictive ballot access environment.

Renewed Organizing and 2024 Campaign

Medical cannabis advocates regrouped in 2022, forming a new coalition called Nebraskans for Medical Marijuana Rights. The organization adopted a two-initiative strategy to address legal vulnerabilities from the 2020 attempt. Initiative 437 focused on establishing the constitutional right to medical cannabis for patients with qualifying conditions, while Initiative 438 created the regulatory framework for cultivation, distribution, and sale. The dual-initiative approach responded to Nebraska's single-subject rule, which requires ballot measures to address only one topic. By separating constitutional authorization from regulatory implementation, organizers sought to insulate the measures from legal challenges based on the single-subject doctrine. The signature-gathering campaign launched in January 2024 and collected more than 220,000 signatures by the July deadline. The Nebraska Secretary of State certified both initiatives for the November 2024 ballot in August 2024, setting up a high-stakes election campaign.

The 2024 Election

Initiative 437 passed with 58.2% voter support, while Initiative 438 received 56.7% approval on November 5, 2024. The measures carried 65 of Nebraska's 93 counties, including Douglas County (Omaha) and Lancaster County (Lincoln), the state's two most populous jurisdictions. Rural counties in western Nebraska showed stronger opposition, with 23 counties rejecting both measures. The victory reflected shifting public opinion on medical cannabis. A University of Nebraska-Lincoln poll conducted in October 2024 found 64% of Nebraskans supported medical marijuana legalization, including 52% of registered Republicans—a significant shift in a state where Republicans hold supermajorities in the legislature.

Post-Election Legal Challenges

Within days of the election, opponents filed suit in Lancaster County District Court seeking to invalidate both initiatives. The lawsuit, brought by former State Senator John Kuehn and supported by the anti-legalization group Protect Our Kids Nebraska, alleged that the measures violated Nebraska's single-subject rule by addressing multiple topics including patient access, regulatory structure, taxation, and criminal penalties. Lancaster County District Judge Susan Strong issued a preliminary injunction in December 2024, temporarily blocking implementation while the case proceeded. The injunction prevented the Nebraska Department of Health and Human Services from accepting license applications or establishing regulatory rules. The case advanced to the Nebraska Supreme Court in March 2025 after Judge Strong ruled in favor of the plaintiffs, declaring both initiatives invalid. The state attorney general's office, representing the Department of Health and Human Services, appealed the decision, arguing that the initiatives satisfied single-subject requirements and that voter intent should be respected. Oral arguments before the Nebraska Supreme Court occurred on June 15, 2026, with a seven-justice panel hearing two hours of testimony. The court took the case under advisement and issued its decision on September 4, 2026.

The Supreme Court Decision

The Nebraska Supreme Court reversed the district court ruling in a 5-2 decision, holding that Initiatives 437 and 438 complied with the state constitution's single-subject rule. Chief Justice Michael Heavican wrote the majority opinion, concluding that both measures addressed the singular topic of medical cannabis access and that regulatory provisions were "reasonably germane" to that central purpose. The majority opinion rejected arguments that the initiatives impermissibly combined multiple subjects, noting that Nebraska courts have historically interpreted the single-subject rule liberally to respect voter sovereignty. The court distinguished the medical cannabis initiatives from previous ballot measures struck down for single-subject violations, emphasizing that all provisions related directly to establishing and regulating a medical marijuana program. Justice Lindsey Miller-Lerman authored a dissenting opinion joined by Justice Jonathan Papik, arguing that the initiatives improperly combined constitutional amendments with statutory regulatory schemes and that the measures should have been separated into additional ballot questions.

Key Players

Nebraska Department of Health and Human Services

The Nebraska Department of Health and Human Services serves as the primary regulatory authority for the medical cannabis program under Initiative 438. The agency is responsible for licensing dispensaries, cultivation facilities, testing laboratories, and product manufacturers. DHHS must also establish the patient registry system, develop quality control standards, and enforce compliance with program rules. Director Dannette Smith announced in September 2026 that the agency would immediately begin rulemaking proceedings to implement the program. DHHS has requested a $4.2 million appropriation from the legislature for initial startup costs, including hiring 18 full-time employees to staff the medical cannabis division.

Nebraskans for Medical Marijuana Rights

Nebraskans for Medical Marijuana Rights led the successful 2024 ballot initiative campaign. The organization, founded by State Senator Anna Wishart and advocate Crista Eggers, raised $3.8 million for the campaign, with major contributions from the Marijuana Policy Project and individual donors. Following the Supreme Court victory, the group transitioned to an educational role, developing resources for patients and healthcare providers.

Nebraska Medical Association

The Nebraska Medical Association maintained official neutrality during the ballot initiative campaigns but has since engaged with program implementation. The organization represents more than 3,000 physicians across the state. NMA President Dr. Janis Holtzclaw said in September 2026 that the association would develop continuing medical education courses on medical cannabis therapeutics and certification procedures.

Protect Our Kids Nebraska

Protect Our Kids Nebraska led opposition to the medical cannabis initiatives, arguing that legalization would increase youth access and normalize marijuana use. The group, chaired by former State Senator John Kuehn, raised $1.2 million for the campaign against the measures. Following the Supreme Court decision, the organization announced it would shift focus to advocating for strict regulatory controls and opposing any future recreational cannabis initiatives.

Multi-State Operators

Several multi-state cannabis operators have expressed interest in entering the Nebraska market. Trulieve, the nation's largest cannabis company by revenue, announced in September 2026 that it would apply for Nebraska licenses. Green Thumb Industries and Curaleaf have also indicated plans to pursue Nebraska operations. These companies bring operational expertise and capital resources but face competition from local applicants who may receive preferential treatment under social equity provisions in Initiative 438.

Nebraska State Patrol

The Nebraska State Patrol opposed the medical cannabis initiatives during the campaign but has committed to professional implementation following the Supreme Court decision. Colonel John Bolduc said in September 2026 that the agency would develop training protocols for troopers on distinguishing legal medical cannabis possession from criminal activity. The patrol has requested funding for additional drug recognition experts and updated roadside testing equipment.

Legal and Regulatory Framework

Nebraska's medical cannabis program operates under a dual constitutional and statutory framework established by Initiative 437 and Initiative 438, creating patient protections while imposing strict regulatory controls on cultivation, distribution, and use. Initiative 437 amended the Nebraska Constitution to establish the right of patients with qualifying medical conditions to access medical cannabis upon recommendation from a licensed physician. The constitutional amendment provides legal protection against state criminal prosecution for possession, use, and transport of medical cannabis within statutory limits. Initiative 438 enacted statutory provisions codified in Nebraska Revised Statutes Chapter 71, Article 47. The statute designates the Nebraska Department of Health and Human Services as the regulatory authority and establishes licensing categories for medical cannabis businesses.

Qualifying Conditions

The program authorizes medical cannabis recommendations for patients diagnosed with: cancer, glaucoma, HIV/AIDS, post-traumatic stress disorder, amyotrophic lateral sclerosis, Crohn's disease, ulcerative colitis, Huntington's disease, autism spectrum disorder, chronic pain, severe nausea, seizures, persistent muscle spasms, and any terminal illness with a life expectancy of less than one year. The DHHS director has authority to add conditions through rulemaking.

Possession and Purchase Limits

Registered patients may possess up to 2.5 ounces of medical cannabis flower or equivalent amounts of cannabis products during any 14-day period. The statute prohibits home cultivation by patients, requiring all medical cannabis to be purchased from licensed dispensaries. Patients may designate caregivers to purchase and transport medical cannabis on their behalf.

Licensing Structure

Initiative 438 establishes five license categories: cultivation facilities, product manufacturers, testing laboratories, dispensaries, and transporters. The statute caps the total number of cultivation licenses at 20 statewide for the first two years of operations, with no limit on dispensary licenses. Counties and municipalities retain authority to prohibit medical cannabis businesses through local ordinances. License applicants must demonstrate Nebraska residency for at least two years, pass background checks, and meet financial suitability requirements. The statute includes social equity provisions granting preferential scoring to applicants from communities disproportionately impacted by cannabis prohibition, military veterans, and family farmers.

Taxation

Medical cannabis sales are subject to a 7% excise tax in addition to state and local sales taxes. The excise tax revenue is deposited in the Medical Cannabis Fund, with allocations for regulatory costs (60%), substance abuse treatment programs (25%), and public education campaigns (15%). The statute prohibits municipalities from imposing additional local excise taxes on medical cannabis.

Employment and Housing Protections

Initiative 438 provides limited employment protections, prohibiting employers from discriminating against registered patients solely based on patient status. However, the statute preserves employer rights to maintain drug-free workplace policies and to discipline employees for impairment during work hours. The law does not require employers to accommodate on-site cannabis use or possession. Landlords may not refuse to rent to registered patients based solely on patient status, but property owners retain authority to prohibit cannabis use on their premises through lease provisions.

Federal Law Considerations

Medical cannabis remains prohibited under the federal Controlled Substances Act, 21 U.S.C. § 812, which classifies marijuana as a Schedule I controlled substance. The Nebraska program operates in tension with federal law, relying on prosecutorial discretion and the Rohrabacher-Farr Amendment, which prohibits the Department of Justice from using federal funds to interfere with state medical cannabis programs. The September 2026 Supreme Court decision addressed federal preemption arguments, holding that state authorization of medical cannabis does not violate the Supremacy Clause because Nebraska law does not require conduct that federal law prohibits. The court noted that state legalization merely removes state-level penalties while federal prohibition remains in effect.

State-by-State Context

Nebraska's medical cannabis program positions the state within a regional landscape where all neighboring jurisdictions have authorized some form of marijuana access, ending Nebraska's status as a prohibition holdout in the Great Plains.

Iowa

Iowa operates a limited medical cannabidiol program established in 2014 and expanded in 2020. The program allows patients with qualifying conditions to access low-THC cannabis products containing no more than 4.5 grams of THC per 90-day period. Iowa's restrictive approach contrasts sharply with Nebraska's more comprehensive program, which does not impose THC limits on medical cannabis products.

Missouri

Missouri voters approved medical cannabis in 2018 and recreational marijuana in 2022. The state's mature medical program includes more than 190 licensed dispensaries and serves approximately 250,000 registered patients. Missouri's experience provides a template for Nebraska's implementation, particularly regarding licensing procedures and product testing standards. Missouri patients may possess up to four ounces of cannabis flower, significantly higher than Nebraska's 2.5-ounce limit.

South Dakota

South Dakota voters approved medical cannabis in 2020, with the program launching in 2021. The state licenses cultivation facilities, dispensaries, and testing laboratories under oversight by the South Dakota Department of Health. South Dakota's program allows patients to possess up to three ounces of cannabis, and unlike Nebraska, permits home cultivation of up to three plants. Approximately 8,500 patients are registered in South Dakota's program as of 2026.

Kansas

Kansas remains one of the few states without any legal cannabis program, maintaining full prohibition of marijuana for medical and recreational purposes. Kansas legislators have introduced medical cannabis bills in recent sessions, but none have advanced to floor votes. Nebraska's implementation may increase pressure on Kansas lawmakers to reconsider their position, particularly as patients in border counties gain legal access to medical cannabis in Nebraska.

Colorado

Colorado legalized medical cannabis in 2000 and recreational marijuana in 2012, operating the nation's most mature cannabis market. Colorado's medical program serves approximately 80,000 registered patients and includes more than 500 licensed dispensaries. The state's experience with regulatory challenges, including diversion concerns and product safety standards, offers lessons for Nebraska regulators. Colorado patients may possess up to two ounces of cannabis flower.

Wyoming

Wyoming maintains cannabis prohibition with no medical or recreational program. The state legislature has repeatedly rejected medical cannabis proposals, most recently in 2024. Wyoming's continued prohibition creates potential border dynamics with Nebraska, as Wyoming residents may attempt to access Nebraska's medical program through fraudulent residency claims.

Market and Business Implications

Nebraska's medical cannabis market is projected to generate $50 million to $80 million in annual sales by year three, attracting multi-state operators and local entrepreneurs while creating approximately 1,500 direct jobs across cultivation, retail, and ancillary sectors. The Nebraska market presents unique characteristics compared to coastal states with established cannabis industries. The state's rural geography, agricultural economy, and conservative regulatory approach will shape market development. Industry analysts project Nebraska will follow a growth trajectory similar to Arkansas and Oklahoma, both of which launched medical programs in conservative states with agricultural traditions.

Licensing Economics

Initiative 438 establishes application fees of $5,000 for all license categories, with annual renewal fees of $10,000 for cultivation facilities, $5,000 for dispensaries, and $3,000 for testing laboratories. The fee structure is designed to generate revenue for regulatory oversight while remaining accessible to small business applicants. The 20-license cap on cultivation facilities during the first two years creates significant scarcity value. Industry consultants estimate that successful cultivation licenses could generate $3 million to $8 million in annual revenue depending on wholesale pricing and production capacity. Multi-state operators with access to capital and operational expertise hold competitive advantages in securing cultivation licenses, though social equity provisions may benefit local applicants. Dispensary licenses face no numerical cap, allowing market forces to determine the number of retail locations. However, local control provisions enable counties and municipalities to prohibit dispensaries through ordinances, potentially limiting retail access in rural areas. Industry projections estimate 40 to 60 dispensaries will open statewide during the first year of operations.

Wholesale and Retail Pricing

Wholesale cannabis pricing in Nebraska is expected to range from $1,800 to $2,500 per pound during the first year of operations, based on pricing patterns in comparable markets. Retail prices for medical cannabis flower are projected at $10 to $15 per gram, with cannabis oil products ranging from $40 to $80 per gram depending on potency and formulation. Pricing will be influenced by several factors including production costs, regulatory compliance expenses, excise taxes, and competition from neighboring state markets. Nebraska's prohibition on home cultivation eliminates competition from personal grows, potentially supporting higher retail prices compared to states that allow patient cultivation.

Section 280E Impact

Cannabis businesses operating in Nebraska will face federal tax burdens under Internal Revenue Code Section 280E, which prohibits businesses trafficking in Schedule I controlled substances from deducting ordinary business expenses. Section 280E creates effective tax rates of 60% to 80% for cannabis retailers, significantly impacting profitability. Multi-state operators have developed sophisticated tax planning strategies to minimize 280E impact, including cost-of-goods-sold optimization and vertical integration structures. Local Nebraska operators entering the industry will need accounting expertise to navigate 280E compliance while maintaining profitability.

Capital Formation

Nebraska cannabis businesses face challenges accessing traditional banking services due to federal prohibition. Most banks and credit unions avoid cannabis clients to prevent potential violations of federal money laundering statutes and Bank Secrecy Act requirements. The SAFE Banking Act, which would protect financial institutions serving state-legal cannabis businesses, has not passed Congress as of September 2026. Limited banking access forces many cannabis businesses to operate on a cash basis, creating security risks and operational inefficiencies. Some Nebraska credit unions and community banks may choose to serve medical cannabis businesses, accepting the compliance burden and regulatory risk in exchange for deposits and fee income.

Employment and Economic Development

The medical cannabis industry is projected to create 1,200 to 1,500 direct jobs in Nebraska during the first two years of operations, including cultivation technicians, dispensary staff, laboratory analysts, and compliance personnel. Indirect employment in construction, security, legal services, and accounting could add another 500 to 800 jobs. Rural counties that approve cultivation facilities will see the largest economic impact, as cannabis cultivation requires warehouse space, utilities, and agricultural labor. A typical 30,000-square-foot cultivation facility employs 40 to 60 workers and generates $200,000 to $400,000 in annual local tax revenue through property taxes and sales taxes on supplies.

What Experts Say

Healthcare providers, legal scholars, and industry analysts have offered varied perspectives on the Nebraska Supreme Court decision and the medical cannabis program's implementation challenges. Dr. Janis Holtzclaw, president of the Nebraska Medical Association, said in a September 2026 statement that physicians need comprehensive education on cannabis therapeutics before certifying patients. The association is developing continuing medical education courses covering endocannabinoid system pharmacology, drug interactions, and appropriate patient selection. Holtzclaw emphasized that medical cannabis should be treated like any other medication, with evidence-based prescribing practices and careful monitoring of patient outcomes. Professor Eric Berger of the University of Nebraska College of Law told the Lincoln Journal Star that the Supreme Court decision reflects a pragmatic approach to ballot initiative interpretation. Berger noted that Nebraska courts have historically deferred to voter intent when evaluating single-subject challenges, and the medical cannabis ruling continues that tradition. He said the decision provides clarity for future ballot initiatives by establishing that comprehensive regulatory schemes can satisfy single-subject requirements if all provisions relate to a central purpose. Andrew Livingston, director of economics and research at Vicente Sederberg LLP, a cannabis-focused law firm, said in a September 2026 analysis that Nebraska's market will likely develop more slowly than coastal states due to conservative regulatory approach and limited cultivation licenses. Livingston projected that Nebraska would see 50,000 to 75,000 registered patients by year three, representing approximately 3% to 4% of the state's adult population. He noted that rural geography may limit patient access in western counties where dispensaries are unlikely to open due to local opposition. Crista Eggers, co-founder of Nebraskans for Medical Marijuana Rights, said in a press conference following the Supreme Court decision that the ruling vindicates years of grassroots organizing and patient advocacy. Eggers emphasized that implementation must prioritize patient access and affordability, particularly for low-income Nebraskans who cannot afford high-priced medical cannabis products. She called on regulators to expedite licensing to ensure dispensaries open by mid-2027. Dr. Sue Sisley, a physician and cannabis researcher based in Arizona, told the Omaha World-Herald that Nebraska's qualifying condition list appropriately balances patient access with medical evidence. Sisley noted that conditions like PTSD, chronic pain, and cancer have the strongest clinical evidence supporting cannabis therapeutics. She cautioned that physicians should carefully evaluate patients before recommending medical cannabis and should consider it as one tool among many treatment options. John Kuehn, chairman of Protect Our Kids Nebraska, said following the Supreme Court decision that his organization would monitor implementation closely to ensure strict regulatory enforcement. Kuehn expressed particular concern about diversion to minors and impaired driving. He called on the Nebraska Department of Health and Human Services to establish robust tracking systems and to coordinate with law enforcement on compliance monitoring.

What's Next

Implementation of Nebraska's medical cannabis program will proceed through a multi-phase timeline extending from fall 2026 through mid-2027, with regulatory rulemaking, license application periods, and facility inspections preceding the first dispensary openings. The Nebraska Department of Health and Human Services announced on September 5, 2026, that it would publish emergency rules for the medical cannabis program by October 15, 2026. The emergency rules will establish initial licensing procedures, application requirements, and operational standards to enable rapid program launch. Permanent rules will follow a standard rulemaking process including public comment periods and legislative review. The license application period is scheduled to open on December 1, 2026, for all license categories. DHHS will accept applications on a rolling basis, with initial cultivation and dispensary licenses expected to be awarded by February 2027. The agency has indicated it will prioritize processing cultivation facility applications to ensure adequate supply before dispensaries open. Patient registry enrollment is projected to begin in January 2027, allowing patients to register and obtain medical cannabis identification cards before dispensaries open. The registry will operate through an online portal where patients submit physician certifications and pay a $50 annual registration fee. DHHS estimates processing times of 10 to 15 business days for complete applications. The first dispensaries are projected to open in May or June 2027, approximately eight months after the Supreme Court decision. Omaha and Lincoln will likely see the first retail locations due to population density and existing commercial real estate infrastructure. Rural areas may wait longer for dispensary access depending on local ordinances and business interest. Several municipalities have already begun considering local control ordinances. The Omaha City Council scheduled a public hearing for October 2026 to discuss regulations for medical cannabis businesses, including zoning restrictions and operating requirements. Lincoln officials have indicated they will allow medical cannabis businesses but may impose buffer zones around schools and daycare centers. The Nebraska Legislature will consider appropriations for the medical cannabis program during the 2027 legislative session beginning in January. DHHS has requested $4.2 million for startup costs and ongoing operations. Lawmakers may also consider technical corrections to Initiative 438, though any substantive changes would require voter approval. Legal challenges remain possible despite the Supreme Court decision. Opponents could seek federal court intervention arguing that state authorization of medical cannabis violates the Controlled Substances Act, though such challenges have consistently failed in other states. The U.S. Department of Justice has not indicated any intention to interfere with state medical cannabis programs. Industry observers expect rapid market development once dispensaries open. Multi-state operators are positioning to enter Nebraska through license applications and potential acquisitions of local license holders. Ancillary businesses including security companies, testing laboratories, and compliance software providers are establishing Nebraska operations. Patient advocacy groups are developing educational resources to help Nebraskans navigate the new program. Nebraskans for Medical Marijuana Rights is creating a patient guide covering registration procedures, physician consultations, and product selection. The organization is also advocating for telemedicine access to medical cannabis certifications for rural patients who lack nearby physicians willing to recommend cannabis. The Nebraska Medical Association will launch continuing medical education courses on medical cannabis in early 2027. The courses will cover pharmacology, drug interactions, dosing guidelines, and legal responsibilities for certifying physicians. The association expects several hundred physicians to complete the training during the first year.

Further Reading

• Initiative 437 full text - Nebraska Secretary of State official ballot language and constitutional amendment text
• Initiative 438 full text - Nebraska Secretary of State official ballot language and statutory provisions
• Nebraska Supreme Court decision in Kuehn v. State (September 4, 2026) - Full majority and dissenting opinions
• Nebraska Revised Statutes Chapter 71, Article 47 - Medical Cannabis Act statutory codification
• Nebraska Department of Health and Human Services Medical Cannabis Division - Official regulatory agency page with rulemaking documents and licensing information
• 21 U.S.C. § 812 - Federal Controlled Substances Act Schedule I classification
• Rohrabacher-Farr Amendment - Congressional appropriations rider prohibiting DOJ interference with state medical cannabis programs
• Internal Revenue Code Section 280E - Federal tax code provision affecting cannabis business deductions
• Nebraska Medical Association medical cannabis resources - Physician education materials and practice guidelines
• Marijuana Policy Project Nebraska page - Advocacy organization tracking implementation and policy developments

Update — September 7, 2026: Nebraska Supreme Court Upholds Medical Cannabis Laws

The Nebraska Supreme Court upheld the state's voter-approved medical cannabis laws, rejecting a challenge that sought to overturn the November 2024 ballot measures. The decision clears the path for the Nebraska Medical Cannabis Commission to continue implementing the regulatory framework established by Initiative Measures 437 and 438, which legalized medical cannabis possession and established a licensed cultivation and distribution system.

Opponents had argued the initiatives violated the state constitution's single-subject rule by combining legalization with regulatory structure in separate measures. The court found the measures sufficiently distinct and constitutionally compliant, according to the majority opinion. No stay was issued, meaning the Department of Health and Human Services can proceed with licensing applications for cultivation facilities, testing laboratories, and dispensaries.

The ruling comes nearly two years after 68% of Nebraska voters approved the medical cannabis program in the 2024 general election. State officials had paused certain licensing timelines pending the court's decision, delaying the anticipated spring 2026 opening of the first dispensaries. Industry analysts now expect the first licensed sales by late 2026 or early 2027, contingent on facility inspections and final product testing protocols.

This decision matters because it removes the primary legal obstacle threatening Nebraska's medical cannabis program. Patients with qualifying conditions—including cancer, glaucoma, and post-traumatic stress disorder—can now expect access within months rather than facing indefinite delays. For operators who invested in real estate and preliminary infrastructure, the ruling provides regulatory certainty and confirms that cultivation and dispensary licenses will proceed under the existing application framework without legislative revision.

Nebraska becomes one of the final Midwestern states to operationalize medical cannabis following voter approval, joining a regional market that includes Missouri, Oklahoma, and South Dakota. The court's decision is final, with no further appeals available under Nebraska law.